Comparison of cost of care in patients with flares vs. remission in ulcerative colitis: A perspective from a developing country

溃疡性结肠炎病情发作期与缓解期患者医疗费用比较:来自发展中国家的视角

阅读:3

Abstract

Ulcerative colitis (UC) is a chronic relapsing-remitting disease that results in not only physical, mental and social, but also a significant financial burden to patients and their caregivers. The present study aimed to analyse the monthly cost of care for patients with UC in remission during their regular follow-up and compare this to the expenses born during an episode of acute exacerbation in order to estimate the costs of such episodes of acute severe UC (ASUC). Patients in remission defined using the simple clinical colitis activity index (SCCAI) of <3 were recruited from the outpatient department. Patients with flares were those requiring admission for ASUC. Demographic and clinical data were recorded for each patient. A prevalence-based, micro-costing, human capital approach was used to estimate the direct and indirect monthly per capita mean cost-of-illness. The present study enrolled 25 patients with UC who were in remission (SCCAI of <3) and 51 patients with UC who presented with flares and required hospitalisation for ASUC between January, 2022 to June, 2024. The average monthly cost of care for patients with UC in remission in a tertiary government setup was calculated to be 4,112/- INR. The direct medical cost was 3,676/- INR and the direct non-medical cost was 435/- INR. The cost of management of an episode of ASUC was 44,634/- INR per individual per episode. The direct medical cost was 20,038/- INR, the direct non-medical cost was 4,087/- INR and the indirect cost was 20,509/- INR. The cost of the flares managed surgically was 155,967±100,554/- INR, which was significantly higher than that of flares managed medically (26,922±22,751/- INR; P<0.001). The cost of illness during episodes of acute flares contribute disproportionately to a high financial burden in care of patients with UC. Direct medical costs due to the cost of medications is a major contributor to the cost of care for patients with UC in remission whereas during a period of flares, the indirect cost due to productivity loss is responsible for the majority of the financial burden.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。